A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)

  • Gillman, Andrew (Primary Chief Investigator (PCI))
  • Hazard, Anita (Project Manager)

Project: Research

Project Details

Effective start/end date8/09/237/09/25


  • Clinical trial
  • D9180C00008